Company news

Santen Pharmaceutical Co., Ltd. news in 2026

Santen Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Summary of Consolidated Financial Results for the Six Months Ended September 30, 2026 (IFRS)

November 5, 2026

Santen Announces Share Buyback

November 5, 2026

Santen Announces Change of Major Shareholder

October 26, 2026

Notice Regarding the Petition for Commencement of Bankruptcy Proceedings of a Consolidated Subsidiary

October 16, 2026

Notice on the Completion of Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan

September 30, 2026

New Drug Application Filing Accepted for Review in China for STN1012700 (Atropine Sulfate Ophthalmic Solution 0.025%), an Ophthalmic Solution to Slow the Progression of Myopia

September 14, 2026

Notice on the Disposal of Treasury Shares for the Post-delivery Type Performance-Linked Stock Remuneration Plan

September 3, 2026

Summary of Consolidated Financial Results for the Three Months Ended June 30, 2026 (IFRS)

August 6, 2026

Santen Pharmaceutical: China Signs Exclusive Distribution and Promotion Agreement for Five Marketed Glaucoma Eyedrops Products in the Chinese Mainland

April 16, 2026

Notice of Board of Director and Corporate Auditor Nominations

March 19, 2026

RVL Pharmaceuticals Announces Santen Obtains Manufacturing and Marketing Approval in Japan for UPNEEQ® Mini Ophthalmic Solution 0.1%

January 8, 2026

Decks in 2026